Avoiding Aldosterone Breakthrough in Hypertensive Diabetics: Role of Azelnidipine
Azelnidipine may contribute to avoid the "aldosterone breakthrough" by its suppressive effects on aldosterone synthesis and secretion
Hypertensive patients with type 2 diabetes carry a high cardiovascular risk. Most patients with hypertension and diabetes face higher mortality due to Heart disease and stroke. Hypertension also markedly increases the macrovascular complications like nephropathy and retinopathy in diabetic patients.
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Azelnidipine, click here
MBBS,MD, DNB (Cardiology)
Dr Prem Aggarwal, (DNB Cardiology) is an Cardiologist by profession and also the Co-founder of Medical Dialogues. An avid researcher, he is currently associated with GB Pant Hospital (GIPMER) New Delhi as a PhD Fellow pursuing his research on the topic of Angioplasties on Surgical Rejects